Bank of Montreal Can Decreases Stock Position in Envista Holdings Corporation $NVST

Bank of Montreal Can cut its position in Envista Holdings Corporation (NYSE:NVST) by 17.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,160 shares of the company’s stock after selling 6,249 shares during the period. Bank of Montreal Can’s holdings in Envista were worth $570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Parallel Advisors LLC boosted its stake in Envista by 100.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after purchasing an additional 1,397 shares during the last quarter. FourThought Financial Partners LLC purchased a new position in shares of Envista in the first quarter worth about $180,000. Vestcor Inc acquired a new position in Envista during the first quarter worth about $211,000. Aigen Investment Management LP purchased a new stake in Envista during the 1st quarter valued at about $274,000. Finally, State of Wyoming raised its holdings in Envista by 121.1% in the 1st quarter. State of Wyoming now owns 16,911 shares of the company’s stock valued at $292,000 after acquiring an additional 9,264 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Mizuho set a $19.00 target price on Envista in a report on Monday, November 3rd. Zacks Research lowered Envista from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. UBS Group upped their target price on Envista from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, July 29th. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, Piper Sandler boosted their price target on shares of Envista from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $21.33.

Envista Stock Down 1.6%

Shares of NVST opened at $19.09 on Tuesday. The company’s 50-day moving average price is $20.26 and its 200 day moving average price is $19.74. Envista Holdings Corporation has a 12-month low of $14.22 and a 12-month high of $22.68. The company has a current ratio of 2.44, a quick ratio of 2.08 and a debt-to-equity ratio of 0.46. The firm has a market cap of $3.14 billion, a P/E ratio of 59.64, a price-to-earnings-growth ratio of 1.09 and a beta of 1.05.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Envista had a net margin of 2.11% and a return on equity of 4.84%. The business had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. During the same period last year, the business earned $0.12 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, sell-side analysts forecast that Envista Holdings Corporation will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.